FI954914A0 - Hyaluronihappoa ja NSAID:tä sisältävät koostumukset angiogeneesin eston, säätelyn tai regression aikaansaamiseksi - Google Patents

Hyaluronihappoa ja NSAID:tä sisältävät koostumukset angiogeneesin eston, säätelyn tai regression aikaansaamiseksi

Info

Publication number
FI954914A0
FI954914A0 FI954914A FI954914A FI954914A0 FI 954914 A0 FI954914 A0 FI 954914A0 FI 954914 A FI954914 A FI 954914A FI 954914 A FI954914 A FI 954914A FI 954914 A0 FI954914 A0 FI 954914A0
Authority
FI
Finland
Prior art keywords
hyaluronic acid
angiogenesis
control
nsain
regression
Prior art date
Application number
FI954914A
Other languages
English (en)
Swedish (sv)
Other versions
FI954914A (fi
Inventor
Derek A Willoughby
Chandan Alam
Samuel Simon Asculai
Rudolf Edgar Falk
David William Harper
Original Assignee
Hyal Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyal Pharma Corp filed Critical Hyal Pharma Corp
Publication of FI954914A0 publication Critical patent/FI954914A0/fi
Publication of FI954914A publication Critical patent/FI954914A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Filters For Electric Vacuum Cleaners (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
FI954914A 1993-04-16 1995-10-16 Hyaluronihappoa ja NSAID:tä sisältävät koostumukset angiogeneesin eston, säätelyn tai regression aikaansaamiseksi FI954914A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002094203A CA2094203A1 (en) 1993-04-16 1993-04-16 Inhibition of angiogenesis
CN94192096A CN1123005A (zh) 1993-04-16 1994-04-15 用于抑制、控制和消退血管生成的含有透明质酸和nsaid的组合物
PCT/CA1994/000207 WO1994023725A1 (en) 1993-04-16 1994-04-15 Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and nsaid

Publications (2)

Publication Number Publication Date
FI954914A0 true FI954914A0 (fi) 1995-10-16
FI954914A FI954914A (fi) 1995-11-06

Family

ID=37089291

Family Applications (1)

Application Number Title Priority Date Filing Date
FI954914A FI954914A (fi) 1993-04-16 1995-10-16 Hyaluronihappoa ja NSAID:tä sisältävät koostumukset angiogeneesin eston, säätelyn tai regression aikaansaamiseksi

Country Status (18)

Country Link
EP (1) EP0695187B1 (fi)
JP (1) JPH08508505A (fi)
CN (1) CN1123005A (fi)
AT (1) ATE226827T1 (fi)
AU (2) AU694113B2 (fi)
BR (1) BR9405781A (fi)
CA (1) CA2094203A1 (fi)
CZ (1) CZ267995A3 (fi)
DE (1) DE69431623D1 (fi)
FI (1) FI954914A (fi)
HU (2) HUT74462A (fi)
IL (1) IL109293A (fi)
NO (1) NO954073L (fi)
PL (1) PL306806A1 (fi)
SG (1) SG48924A1 (fi)
SK (1) SK126595A3 (fi)
WO (1) WO1994023725A1 (fi)
ZA (1) ZA942597B (fi)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935860A (en) * 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
CA2154103C (en) * 1995-07-18 1998-02-24 Samuel Simon Asculai Treatment of mucous membrane disease, trauma or condition and for the relief of pain
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
DK1586322T3 (da) * 1996-11-05 2008-12-01 Childrens Medical Center Sammensætninger indeholdende thalidomid og dextamethason til behandling af cancer
WO1998042329A1 (fr) * 1997-03-21 1998-10-01 Mitsubishi Chemical Corporation Preventifs et/ou remedes destines a des affections provoquees par une neovascularisation anormale
US6596703B1 (en) 1997-07-11 2003-07-22 Jagotec Ag Promotion of wound healing utilizing steroids having reduced deteriorous systemic side effects typical of glucocorticoids, mineralocorticoids and sex steroids
KR20010113642A (ko) 1999-01-13 2001-12-28 추후기재 약물의 효능을 증대시키기 위한 조성물 및 증대 방법
JP4587148B2 (ja) * 2000-03-24 2010-11-24 生化学工業株式会社 平滑筋細胞増殖促進剤
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
ITPD20020003A1 (it) * 2002-01-11 2003-07-11 Fidia Advanced Biopolymers Srl Biomateriali a base di acido ialuronico come terapia anti-angiogenicanella cura dei tumori.
ITMI20040347A1 (it) * 2004-02-26 2004-05-26 Pharma Medical Ltd Nuovo farmaco di associazione
CN103784960A (zh) 2005-07-27 2014-05-14 阿尔卡米亚肿瘤学股份有限公司 使用乙酰透明质酸的治疗方案
CN101287475B (zh) 2005-09-07 2012-11-14 阿尔卡米亚肿瘤学股份有限公司 包含透明质酸和治疗抗体的治疗组合物以及制药用途
EA015702B1 (ru) * 2007-05-28 2011-10-31 Винченцо Массимо Ломбардо Противовоспалительная и анальгетическая композиция для местного применения в области опорно-двигательного аппарата животного
EP2567697A1 (en) * 2011-09-12 2013-03-13 Almirall, S.A. Topical pharmaceutical compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
CA2061566C (en) * 1992-02-20 2002-07-09 Rudolf E. Falk Treatment of disease employing hyaluronic acid and nsaids

Also Published As

Publication number Publication date
EP0695187A1 (en) 1996-02-07
AU6561694A (en) 1994-11-08
WO1994023725A1 (en) 1994-10-27
EP0695187B1 (en) 2002-10-30
BR9405781A (pt) 1996-01-16
HU9500113D0 (en) 1995-03-28
NO954073D0 (no) 1995-10-13
AU694113B2 (en) 1998-07-16
NO954073L (no) 1995-12-04
CN1123005A (zh) 1996-05-22
ATE226827T1 (de) 2002-11-15
FI954914A (fi) 1995-11-06
HU211954A9 (en) 1996-01-29
DE69431623D1 (de) 2002-12-05
ZA942597B (en) 1995-02-08
CA2094203A1 (en) 1994-10-17
CZ267995A3 (en) 1996-10-16
HUT74462A (en) 1996-12-30
IL109293A (en) 1999-01-26
IL109293A0 (en) 1994-07-31
PL306806A1 (en) 1995-04-18
SG48924A1 (en) 1998-05-18
AU6994198A (en) 1998-07-23
JPH08508505A (ja) 1996-09-10
SK126595A3 (en) 1997-03-05

Similar Documents

Publication Publication Date Title
FI954914A0 (fi) Hyaluronihappoa ja NSAID:tä sisältävät koostumukset angiogeneesin eston, säätelyn tai regression aikaansaamiseksi
NZ235877A (en) Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence
ATE556705T1 (de) Darreichungsform enthaltend taxol in kristalliner form
AU3664401A (en) Platelet adp receptor inhibitors
CA2260016A1 (en) Substituted pyridines as selective cyclooxygenase-2 inhibitors
WO2001072721A3 (en) Synergistic methods and compositions for treating cancer
ES2165969T3 (es) Compuestos nitrogenados aromaticos condensados 5,5 aril-sustituidos como agentes antiinflamatorios.
CA2219115A1 (en) N-benzyl-3-indoleacetic acids as cyclooxygenase-2-inhibitors and antiinflammatory drugs
DE69825603D1 (de) 2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2
CA2283399A1 (en) Pyridazinones as inhibitors of cyclooxygenase-2
PT773022E (pt) Preparacao farmaceutica para o tratamento de rinites agudas contendo simpaticomimeticos e pantotenol e/ou acido pantotenico
PT97395A (pt) Processo para a preparacao de 2,9-di-substituidas-4h-pirido{1,2-a}-pirimidin-4-onas e de composicoes farmaceuticas que os contem
BR9813319A (pt) Composto, composição farmacêutica para tratamento de infecções bacterianas, e, processos para tratar infecções bacterianas e para preparar um composto
ES2100222T3 (es) Derivados del acido aminoalcansulfonico y compuestos farmaceuticos a utilizar para prevenir o tratar afecciones cardiacas.
AR020226A1 (es) Compuestos para la inhibicion de la secrecion de acido gastrico, procesos para su preparacion, formulaciones farmaceuticas y uso de dichos compuestos parapreparar medicamentos
FI102964B1 (fi) Terapeuttisia yhdisteitä
DE69029693D1 (de) Hydantoin- oder Imidazolidintrionderivate zur Vorbeugung oder Behandlung von Niereninsuffizienz
BR9814498A (pt) Processo para o tratamento de obesidade em um humano necessitando de tal tratamento, composto, uso do mesmo, produto, e, composição farmacêutica
CA2211320A1 (en) 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
WO2002064214A3 (en) Anti cancer combination of substituted pyrroles and paclitaxel
NZ514425A (en) Compositions based on chondroitin sulphate and chitosan for preventing or treating rheumatic disorders by general administration
CA2301590A1 (en) 2-aminopyridines as inhibitors of cyclooxygenase-2
DE69434002D1 (de) 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis
IL149830A0 (en) Dimethylamino (ethylidene) thioamide derivatives, process for their preparation and use thereof in the preparation of angiogenesis inhibitors
WO1999027921A3 (en) Compositions and methods for modulating the activity of fibroblast growth factor